+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Drugs Modifying Catecholamine Synthesis on Plasma LH and Ovulation in the Rat



      S. Karger AG

      Catecholamines, Norepinephrine, Ovulation, LH, Progesterone

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Relatively large doses of alpha methyl paratyrosine ( α-MPT) (400 mg/kg, i.p.) to inhibit catecholamine synthesis were capable of blocking both the pre-ovulatory elevation in plasma LH and ovulation in proestrous rats. Similarly, large doses of diethyldithio-carbamate (DDC) to deplete brain norepinephrine stores also inhibited ovulation and LH release. The blockade induced by α-MPT could not be reversed by the administration of L-dihydroxyphenylalanine (L-dopa) or dihydroxyphenylserine (DOPS). Similarly, neither L-dopa nor DOPS was able to alter the blockade induced by DDC. An injection of progesterone (2 mg/rat, s.c.) increased the plasma LH values on the afternoon of proestrus and the stimulatory effect of progesterone was blocked by the administration of α-MPT prior to progesterone. Although L-dopa failed to reverse the blockade of α-MPT, a partial reversal was obtained by the administration of DOPS. DDC also blocked the progesterone-induced LH release and there was a slight reversal in animals given DOPS together with DDC. Except for the difficulties in reversing the blockade with drugs to augment norepinephrine synthesis, the results are consistent with the hypothesis that norepinephrine is involved in the pre-ovulatory discharge of gonadotropins.

          Related collections

          Author and article information

          S. Karger AG
          25 March 2008
          : 15
          : 2
          : 79-91
          Department of Physiology, University of Texas Health Science Center, Southwestern Medical School, Dallas, Tex.
          122296 Neuroendocrinology 1974;15:79–91
          © 1974 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 13


          Comment on this article